| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3269269 | HPB | 2013 | 7 Pages |
Abstract
BR to initial TACE for unresectable HCC is associated with comparable survival to those without BR in spite of a longer time to cancer progression. It may be reasonable to consider further therapy such as repeat TACE or biological/systemic therapy in patients with HCC even when the radiological response to the initial TACE is favourable.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Jon C. Henry, Lavina Malhotra, Hooman Khabiri, Gregory Guy, Anthony Michaels, James Hanje, Marcela Azevedo, Mark Bloomston, Carl R. Schmidt,